According to incomplete statistics from Innovation Radar, last week (October 13 to October 19)Global Biopharmaceutical Field Discloses 37 Transaction Events with a Potential Total Transaction Value Exceeding $12.7 Billion. Transaction with17 Collaborative R&D ProjectsAnd10 Drug LicensesAs the main form, multinational pharmaceutical companies such as Roche, AstraZeneca, and Novo Nordisk participated in several large transactions.

The largest potential deal last week came fromNovo Nordisk announced on the 15th the acquisition of Omeros Corporation's complement inhibitor zaltenibart (OMS906) for $2.1 billion.Zaltenibart is a human monoclonal antibody targeting the MASP-3 protein, which plays a role in the complement system and is associated with various immune and rare diseases. In a Phase 2 trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) (sample size of 12), Zaltenibart demonstrated a 75% complete response rate. Novo Nordisk plans to initiate a Phase 3 study for PNH and explore the drug's potential in multiple rare blood and kidney disorders. This move is part of Novo Nordisk's recent pipeline adjustments to strengthen its presence in the rare disease field.

Technology-driven cooperation became the highlight of last week, with the application of artificial intelligence (AI) in drug research and development continuing to gain momentum:

October 14,Bristol-Myers Squibb and insitro Announce Extended Collaboration Based on 2020 Agreement to Advance ALS Drug Discovery Using insitro’s AI Platform ChemMLThe platform generates billions of drug target binding and selectivity data through Quantitative Adaptive Libraries (QAL), combined with AI-driven design cycles (Design-Synthesize-Test) to accelerate target translation. This collaboration focuses on novel ALS targets in preclinical discovery, with plans to develop small molecule therapies. The total deal value could exceed $2.02 billion.

On the same day,Takeda and Nabla Bio Reach Over $1 Billion CollaborationThis marks a further deepening of AI-driven biopharmaceutical development between the two parties, following their initial collaboration in 2022. Takeda will utilize Nabla Bio's JAM platform to design antibody drugs from scratch, covering multi-target and multi-specificity therapies.

AstraZeneca and Immunai Extend Three-Year Collaboration with an $85 Million Agreement to Expand Inflammatory Bowel Disease (IBD) Target DiscoveryImmunai Identifies New Targets Through AMICA Cell Atlas and AI Model Called "Immune Kinetics Engine," AstraZeneca Obtains Exclusive Development Rights.

For oral delivery technology,Rani Therapeutics Partners with Chugai Pharmaceutical, a Roche Subsidiary, in a Collaboration Worth Over $1 BillionDeveloping oral formulations of rare disease antibodies based on the oral delivery platform RaniPill to replace traditional injection methods. Rani Therapeutics also secured $60.3 million in private equity financing.

Multiple Outward Licensing and Collaboration Cases from Chinese Companies Last Week Covering Autoimmune and Oncology Fields:

PRIGEN Biotech and Kite Pharma Reach Potential $1.64 Billion Collaboration in In Vivo Gene Editing Therapy FieldThe two parties will accelerate the advancement of proof-of-concept research, focusing on urgent fields such as oncology and autoimmune diseases.

Hansoh Pharma to Grant Roche Global Rights to ADC Drug HS-20110 for $1.53 Billion(Excluding mainland China, Hong Kong, Macao, and Taiwan). The drug is composed of a CDH17-targeted monoclonal antibody linked to a topoisomerase inhibitor (TOPOi) payload through a covalent bond, and early clinical activity has been observed in solid tumors such as colorectal cancer.

V立志博 will grant Dianthus Therapeutics exclusive rights for the research, development, production, and commercialization of LBL-047 outside Greater China, with a total amount up to 1 billion US dollars.LBL-047 is a bispecific fusion protein targeting BDCA2/TACI. It selectively depletes plasmacytoid dendritic cells (pDCs) to reduce type I interferon production while inhibiting the BAFF/APRIL pathway to block B-cell activation. This therapy has the potential to cover multiple autoimmune indications.

In addition,Haihe Biopharma Licenses Exclusive Rights for Development, Manufacturing, and Commercialization of PI3Kα Inhibitor Rigosertib in Japan to Taiho Pharmaceutical, This drug is used to treat patients who have experienced disease progression or recurrence after previous chemotherapy and carryPIK3CAOvarian Clear Cell Carcinoma with Gene Mutations.

For other transactions, see the table below.

Readers, please star ⭐ Chuangjianhui to receive updates第一时间收到推送.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Individuals are welcome to share this to their WeChat Moments. Unauthorized media or institutions are prohibited from reprinting or copying it to other platforms in any form. For authorization to reprint, please contact:"Innovation Insights"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommended

Click "InSee", Share Chuangjian Hui Health New Trends